关于修订日本预防传染病疫苗临床试验指南的建议
该研究通过问卷调查日本制药企业、比较国内外指南并调查2010年4月至2020年12月在日本获批的35种疫苗的审评报告,识别出疫苗开发中的当前挑战。作者建议新疫苗应优先通过多区域临床试验评估保护效力,并提出了联合疫苗比较、非主要受试者免疫原性评估等修订建议。
要点
- 建议新传染病疫苗通过多区域临床试验评估保护效力。
- 若已建立保护效力与免疫原性相关性,可基于免疫原性开展研究。
- 许可联合疫苗添加抗原时,可将许可联合疫苗用作对照。
核心结论
- 建议新传染病疫苗应评估保护效力,最好通过多区域临床试验进行。
- 建议许可联合疫苗在添加抗原时可用作对照。
- 提出非主要受试者(如老年人或免疫功能低下患者)的疫苗效力可通过与已确认保护效力的主要受试者免疫原性比较来评估。
研究设计与样本
- 通过问卷调查日本制药企业、比较国内外指南并调查2010年4月至2020年12月在日本获批的35种疫苗的审评报告,识别疫苗开发中的当前挑战。
主要发现
- 识别的挑战包括:要求保护效力试验、联合疫苗效力评价、多区域和国外临床试验的开发、老年人和免疫功能低下患者的免疫接种。
- 多区域临床试验时,地区间传染病发病率或流行病毒株差异可能影响试验,但若已建立保护效力与免疫原性相关性,可开展基于免疫原性的研究。
关键数值与推荐
- 许可联合疫苗在添加抗原时可用作对照。
- 非主要受试者(如老年人或免疫功能低下患者)的疫苗效力可通过与已确认保护效力的主要受试者免疫原性比较来评估。
临床怎么用
- 作者建议新传染病疫苗应评估保护效力,最好通过多区域临床试验进行。
- 作者建议许可联合疫苗在添加抗原时可用作对照。
- 作者提出非主要受试者(如老年人或免疫功能低下患者)的疫苗效力可通过与已确认保护效力的主要受试者免疫原性比较来评估。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The development of vaccines against infectious diseases requires a different approach from that of therapeutics, because vaccines are inoculated into healthy individuals and have a preventive effect by activating the immunity of the inoculated human. In Japan, "The Guideline for Clinical Trials of Vaccines for the Prevention of Infectious Diseases" was published in 2010 before changes occurred in the vaccine development environment in Japan, such as the introductions of foreign vaccines and simultaneous global development. This study aimed to identify current challenges in vaccine development through a questionnaire-based survey of pharmaceutical companies in Japan and by comparing the domestic and international guidelines and surveying review reports of 35 vaccines approved in Japan between April 2010 and December 2020. Identified challenges included the requirement for protective efficacy trials, efficacy evaluation of combination vaccines, development of multiregional and foreign clinical trials, and immunization of older adults and immunocompromised patients. We propose that new vaccines against infectious diseases should be evaluated for the protective efficacy, preferably through multiregional clinical trials. Additionally, differences in the incidence of infectious diseases or in epidemic virus strains between regions may affect the trials, when multiregional clinical trials are conducted, but immunogenicity-based studies can be conducted if a correlation between protective efficacy and immunogenicity has been established. We suggest that licensed combination vaccines can be used as comparators when an antigen is added to a licensed combination vaccine. We also proposed that the efficacy of a vaccine in non-major subjects, such as older adults or immunocompromised patients could be evaluated by comparing immunogenicity in major subjects with the confirmed protective effects of the vaccine. It is expected that these revisions will lead to the rapid advancement of vaccine development, which should contribute to the improvement of public health.
引用
- Nomura Y, Noda K, Oohashi Y, et al. Proposal for the revision of guidelines for clinical trials of vaccines to prevent infectious diseases in Japan. Vaccine. 2022. PMID: 36167693. doi:10.1016/j.vaccine.2022.09.036
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。